Management of complications of prostate cancer treatment

CA Cancer Journal for Clinicians

Volumn 58, Issue 4, 2008, Pages 196-213

  Michaelson, M Dror ^a   Cotter, Shane E ^b   Gargollo, Patricio C ^a   Zietman, Anthony L ^a   Dahl, Douglas M ^a,c   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; BRAIN INJURY; CANCER RADIOTHERAPY; FLUSHING; GASTROINTESTINAL DISEASE; HORMONAL THERAPY; OSTEOLYSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECTUM INJURY; REVIEW; SEXUAL DYSFUNCTION; URINARY TRACT DISEASE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY CONSERVATION AGENTS; GASTROINTESTINAL DISEASES; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; UROLOGIC DISEASES;

EID: 48149088303     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/CA.2008.0002     Document Type: Review

References (150)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49:282-296.
3. Dahl DM, He W, Lazarus R, et al. Pathologic outcome of laparoscopic and open radical prostatectomy. Urology 2006;68:1253-1256.
4. Eden CG, Cahill D, Vass JA, et al. Laparoscopic radical prostatectomy: the initial UK series. BJU Int 2002;90:876-882.
5. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.
6. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
7. Poulakis V, Ferakis N, Dillenburg W, et al. Laparoscopic radical prostatectomy using an extraperitoneal approach: Nordwest hospital technique and initial experience in 255 cases. J Endourol 2006;20:45-53.
8. Roumeguere T, Bollens R, Vanden Bossche M, et al. Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol 2003;20:360-366.
9. Salomon L, Levrel O, Anastasiadis AG, et al. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach. Prostate Cancer Prostatic Dis 2002;5:285-290.
10. Schraudenbach P, Bermejo CE. Management of the complications of radical prostatectomy. Curr Urol Rep 2007;8:197-202.
11. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492-497.
12. Loughlin K, ed. Complications of laparoscopic radical prostatectomy, in Gargollo P, Dahl DM. Complications of Urologic Surgery and Practice: Diagnosis, Prevention, and Management. New York, NY: Informa Healthcare; 2007.
13. Sterbis JR, Brassell SA, McLeod DG. Perioperative complications of radical retropubic prostatectomy. Clin Genitourin Cancer 2005;4:160-166.
14. Vallancien G, Cathelineau X, Baumert H, et al. Complications of transperitoneal laparoscopic surgery in urology: review of 1,311 procedures at a single center. J Urol 2002;168:23-26.
15. Wagner JR, Russo P. Urologic complications of major pelvic surgery. Semin Surg Oncol 2000;18:216-228.
16. Hu JC, Nelson RA, Wilson TG, et al. Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. J Urol 2006;175:541-546.
17. Bishoff JT, Allaf ME, Kirkels W, et al. Laparoscopic bowel injury: incidence and clinical presentation. J Urol 1999;161:887-890.
18. Chandler JG, Corson SL, Way LW. Three spectra of laparoscopic entry access injuries. J Am Coll Surg 2001;192:478-490.
19. Cadeddu JA, Regan F, Kavoussi LR, Moore RG. The role of computerized tomography in the evaluation of complications after laparoscopic urological surgery. J Urol 1997;158:1349-1352.
20. Bauer JJ, Schulam PG, Kaufman HS, et al. Laparoscopy for the acute abdomen in the postoperative urologic patient. Urology 1998;51:917-919.
21. Burova RA, Tronin RIu, Nesterenko IuA, Grinberg AA. Laparoscopy in the differential diagnosis of acute abdomen [in Russian]. Khirurgiia (Mosk) 1994;3:16-20.
22. Trabulsi EJ, Guillonneau B. Laparoscopic radical prostatectomy. J Urol 2005;173:1072-1079.
23. Guillonneau B, Gupta R, El Fettouh H, et al. Laparoscopic [correction of laproscopic] management of rectal injury during laparoscopic [correction of laproscopic] radical prostatectomy. J Urol 2003;169:1694-1696.
24. Lassen PM, Kearse WS Jr. Rectal injuries during radical perineal prostatectomy. Urology 1995;45:266-269.
25. Katz R, Borkowski T, Hoznek A, et al. Operative management of rectal injuries during laparoscopic radical prostatectomy. Urology 2003;62:310-313.
26. Pisters LL, Wajsman Z. A simple test for the detection of intraoperative rectal injury in major urological pelvic surgery. J Urol 1992;148:354.
27. Borland RN, Walsh PC. The management of rectal injury during radical retropubic prostatectomy. J Urol 1992;147:905-907.
28. Häggman M, Brändstedt S, Norlen BJ. Rectal perforation after retropubic radical prostatectomy: occurrence and management. Eur Urol 1996;29:337-340.
29. Dafnis G, Wang YH, Borck L. Transsphincteric repair of rectourethral fistulas following laparoscopic radical prostatectomy. Int J Urol 2004;11:1047-1049.
30. Gonzalgo ML, Pavlovich CP, Trock BJ, et al. Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy. J Urol 2005;174:135-139.
31. Guillonneau B, Cathelineau X, Doublet JD, et al. Laparoscopic radical prostatectomy: assessment after 550 procedures. Crit Rev Oncol Hematol 2002;43:123-133.
32. Rozet F, Galiano M, Cathelineau X, et al. Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J Urol 2005;174:908-911.
33. Stolzenburg JU, Rabenalt R, Do M, et al. Categorisation of complications of endoscopic extraperitoneal and laparoscopic transperitoneal radical prostatectomy. World J Urol 2006;24:88-93.
34. Bollens R, Vanden Bossche M, Roumeguere T, et al. Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases. Eur Urol 2001;40:65-69.
35. Dahl DM, L'Esperance JO, Trainer AF, et al. Laparoscopic radical prostatectomy: initial 70 cases at a U.S. university medical center. Urology 2002;60:859-863.
36. Hoznek A, Salomon L, Olsson LE, et al. Laparoscopic radical prostatectomy. The Créteil experience. Eur Urol 2001;40:38-45.
37. Raboy A, Ferzli G, Albert P. Initial experience with extraperitoneal endoscopic radical retropubic prostatectomy. Urology 1997;50:849-853.
38. Rassweiler J, Sentker L, Seemann O, et al. Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J Urol 2001;166:2101-2108.
39. Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR. Laparoscopic radical prostatectomy: initial short-term experience. Urology 1997;50:854-857.
40. Türk I, Deger S, Winkelmann B, et al. Laparoscopic radical prostatectomy. Technical aspects and experience with 125 cases. Eur Urol 2001;40:46-52.
41. Salomon L, Sèbe P, De la Taille A, et al. Open versus laparoscopic radical prostatectomy: part I. BJU Int 2004;94:238-243.
42. Davidson PJ, van den Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996;29:168-173.
43. Hedican SP, Walsh PC. Postoperative bleeding following radical retropubic prostatectomy. J Urol 1994;152:1181-1183.
44. Lang GS, Ruckle HC, Hadley HR, et al. One hundred consecutive laparoscopic pelvic lymph node dissections: comparing complications of the first 50 cases to the second 50 cases. Urology 1994;44:221-225.
45. Rassweiler J, Schulze M, Teber D, et al. Laparoscopic radical prostatectomy with the Heilbronn technique: oncological results in the first 500 patients. J Urol 2005;173:761-764.
46. Modi P, Goel R, Dodiya S. Laparoscopic ureteroneocystostomy for distal ureteral injuries. Urology 2005;66:751-753.
47. Reddy PK, Evans RM. Laparoscopic ureteroneocystostomy. J Urol 1994;152:2057-2059.
48. Guillonneau B, Rozet F, Cathelineau X, et al. Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urol 2002;167:51-56.
49. Brown JA, Dahl DM. Transperitoneal laparoscopic radical prostatectomy in patients after laparoscopic prosthetic mesh inguinal herniorrhaphy. Urology 2004;63:380-382.
50. Lieskovsky G, Skinner DG, Weisenburger T. Pelvic lymphadenectomy in the management of carcinoma of the prostate. J Urol 1980;124:635-638.
51. Alibhai SM, Leach M, Tomlinson G, et al. Rethinking 30-day mortality risk after radical prostatectomy. Urology 2006;68:1057-1060.
52. Dillioglugil O, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 1997;157:1760-1767.
53. Geary ES, Dendinger TE, Freiha FS, Stamey TA. Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45:1000-1006.
54. Surya BV, Provet J, Johanson KE, Brown J. Anastomotic strictures following radical prostatectomy: risk factors and management. J Urol 1990;143:755-758.
55. Lepor H, Kaci L, Xue X. Continence following radical retropubic prostatectomy using self-reporting instruments. J Urol 2004;171:1212-1215.
56. Artibani W, Grosso G, Novara G, et al. Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur Urol 2003;44:401-406.
57. Salomon L, Anastasiadis AG, Katz R, et al. Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. Eur Urol 2002;42:338-343.
58. Stolzenburg JU, Truss MC, Bekos A, et al. Does the extraperitoneal laparoscopic approach improve the outcome of radical prostatectomy? Curr Urol Rep 2004;5:115-122.
59. Erdogru T, Teber D, Frede T, et al. Comparison of transperitoneal and extraperitoneal laparoscopic radical prostatectomy using match-pair analysis. Eur Urol 2004;46:312-319.
60. Eden CG, King D, Kooiman GG, et al. Transperitoneal or extraperitoneal laparoscopic radical prostatectomy: does the approach matter? J Urol 2004;172:2218-2223.
61. Konety BR, Sadetsky N, Carroll PR. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume - analysis of data from the CaPSURE Database. J Urol 2007;177:1423-1425.
62. Manassero F, Traversi C, Ales V, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial. Neurourol Urodyn 2007;26:985-989.
63. Nisen H, Perttilä I, Ranta-Knuuttila T, et al. Laparoscopic radical prostatectomy: surgical, oncological and functional outcomes. Scand J Urol Nephrol 2008;42:29-34.
64. Huland H. Radical prostatectomy: options and issues. Eur Urol 2001;39(suppl):3-9.
65. Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172:2227-2231.
66. Steiner MS. Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Semin Urol Oncol 1995;13:204-214.
67. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000;163:1802-1807.
68. Walsh PC, Marschke PL. Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. Urology 2002;59:934-938.
69. Van Kampen M, De Weerdt W, Van Poppel H, et al. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Lancet 2000;355:98-102.
70. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156:1707-1713.
71. Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2007;2:CD001843.
72. Klingler HC, Marberger M. Incontinence after radical prostatectomy: surgical treatment options. Curr Opin Urol 2006;16:60-64.
73. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991;145:998-1002.
74. Walsh PC. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology 2001;57:1020-1024.
75. Walsh PC. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J Urol 2007;177:1632-1635.
76. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55:58-61.
77. Katz R, Salomon L, Hoznek A, et al. Patient reported sexual function following laparoscopic radical prostatectomy. J Urol 2002;168:2078-2082.
78. Rassweiler J, Stolzenburg J, Sulser T, et al. Laparoscopic radical prostatectomy - the experience of the German Laparoscopic Working Group. Eur Urol 2006;49:113-119.
79. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-360.
80. Su LM, Link RE, Bhayani SB, et al. Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. Urology 2004;64:123-127.
81. Pinkawa M, Fischedick K, Asadpour B, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83-9.
82. Prosnitz RG, Schneider L, Manola J, et al. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999;45:563-566.
83. Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994;74:2520-2532.
84. Sandhu AS, Zelefsky MJ, Lee HJ, et al. Longterm urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys 2000;48:643-647.
85. Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996;47:387-394.
86. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358-1367.
87. Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006;66:439-444.
88. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
89. Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007;10:82-86.
90. Sacco DE, Daller M, Grocela JA, et al. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int 2003;91:345-349.
91. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:1085-1092.
92. Elshaikh MA, Ulchaker JC, Reddy CA, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005;62:164-169.
93. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
94. Landis DM, Schultz D, Cormack R, et al. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology 2005;65:750-754.
95. Shah JN, Ennis RD. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. Int J Radiat Oncol Biol Phys 2006;64:817-824.
96. Prada PJ, Fernández J, Martinez AA, et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007;69:95-102.
97. Merrick GS, Butler WM, Wallner KE, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;62:437-447.
98. Potters L, Torre T, Fearn PA, et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-1242.
99. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology 1997;50:920-928.
100. Quek ML, Penson DF. Quality of life in patients with localized prostate cancer. Urol Oncol 2005;23:208-215.
101. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
102. Lee WR, Hall MC, McQuellon RP, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:614-623.
103. Clark JA, Inui TS, Silliman RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21:3777-3784.
104. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-566.
105. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23:2772-2780.
106. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244.
107. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456.
108. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000;55:97-101.
109. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
110. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004;79:1247-1251.
111. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98-102.
112. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973;289:72-80.
113. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984;311:1281-1286.
114. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66:1039-1044.
115. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-941.
116. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
117. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36:1134-1141.
118. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003;8:474-487.
119. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-435.
120. Gagnon JD, Moss WT, Stevens KR. Pre-estrogen breast irradiation for patients with carcinoma of the prostate: a critical review. J Urol 1979;121:182-184.
121. Widmark A, Fosså SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003;61:145-151.
122. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-815.
123. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8:75-83.
124. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561-1566.
125. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222.
126. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186.
127. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
128. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361-2367.
129. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012.
130. Leder BZ, Smith MR, Fallon MA, et al. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001;86:511-516.
131. National Osteoporosis Foundation. Osteoporosis in Men. Available at: http://www.nof.org/men/strategies_men.htm. Accessed March 12, 2008.
132. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84:3431-3434.
133. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897-7903.
134. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
135. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136-139.
136. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.
137. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444-1450.
138. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-1042.
139. Taneja SS, Smith MR, Dalton JT, et al. Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 2006;15:293-305.
140. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
141. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63:742-745.
142. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-4267.
143. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361-3367.
144. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100-104.
145. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201.
146. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-1308.
147. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391-406.
148. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-3983.
149. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188-2194.
150. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-1500.